Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (WISER-NET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03280836
Recruitment Status : Recruiting
First Posted : September 13, 2017
Last Update Posted : December 9, 2019
Sponsor:
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
Kathleen Sturgeon, Milton S. Hershey Medical Center

Brief Summary:
The investigators seek to conduct a home based exercise intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy. The primary aim of the study is to determine whether breast cancer patients can be enrolled, randomized, retained, and comply with exercise program; and, the feasibility of acquiring, managing and analyzing clinical data.

Condition or disease Intervention/treatment Phase
Breast Neoplasm Physical Activity Behavioral: Exercise Not Applicable

Detailed Description:
Several national and international agencies recommend exercise participation for all persons following a cancer diagnosis. The current evidence suggests that aerobic exercise training is safe during primary adjuvant therapy and improves cardiopulmonary function and patient related outcomes. Cardiopulmonary fitness is highly predictive of overall and cardiovascular specific mortality in women. Specifically, an increase in cardiopulmonary fitness of approximately 10% has been associated with a 19% reduction in risk for CV mortality. This is important as breast cancer patients already present at diagnosis with 31% lower cardiopulmonary fitness levels compared to healthy age-matched women. This enhanced risk for cardiovascular mortality in breast cancer patients is further compounded by cardiotoxic chemotherapy, which causes permanent cardiac damage. Few studies have tested the efficacy of exercise prescriptions that incorporate high intensity aerobic exercise training in cancer patients, especially those receiving chemotherapy. Therefore, the investigators seek to conduct an at home aerobic exercise training intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are randomized to the intervention or control arm.
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Women In Steady Exercise Research - Neoadjuvant Exercise Trial
Actual Study Start Date : August 3, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Control
We ask that participants in the control arm do not start an exercise program.
Experimental: Exercise

Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.

Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level.

Behavioral: Exercise

All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.

The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max.





Primary Outcome Measures :
  1. Acceptability: Percent of eligible patients that provide consent and are enrolled in the study. [ Time Frame: 1 year ]
    Acceptability of the study will be assessed by documenting the percent of eligible patients that provide consent and are enrolled in the study.

  2. Feasibility of the study will be assessed by documenting participant adherence to the exercise intervention. [ Time Frame: 18 months ]
    Heart monitors will be used to quantify adherence.

  3. Efficacy of the intervention will be assessed by determining the change in cardiopulmonary fitness level between control and experimental group using cardiopulmonary exercise test [ Time Frame: 18 months ]
    Participants will complete a baseline and follow up cardiopulmonary exercise test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

3.1 Inclusion Criteria

  • Women with a breast cancer diagnosis (Stage I-IIIC)
  • Sedentary (< 75 min/wk of moderate intensity exercise over the past month)
  • No previous history of anthracycline based chemotherapy
  • Absence of heart disease (clinical diagnosis of coronary artery disease, arrhythmias, congenital heart defects, dilated cardiomyopathy, or valvular heart disease)
  • Absence of contraindications for neoadjuvant chemotherapy
  • Scheduled to receive neoadjuvant chemotherapy
  • Primary attending oncologist approval

3.2 Exclusion Criteria

  • Absolute contraindications for exercise stress testing

    • acute myocardial infarction (3-5 days)
    • unstable angina
    • uncontrolled arrhythmias causing symptoms or hemodynamic compromise
    • syncope
    • acute endocarditis
    • acute myocarditis or pericarditis
    • uncontrolled heart failure
    • acute pulmonary embolus or pulmonary infarction
    • thrombosis of lower extremities
    • suspected dissecting aneurysm
    • uncontrolled asthma
    • pulmonary edema
    • room air desaturation at rest ≤85%
    • respiratory failure
    • acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
    • mental impairment leading to inability to cooperate
    • decisional impairment
  • Non-English speaking
  • Women only diagnosed with ductal carcinoma in situ
  • Women diagnosed with stage 4 metastatic breast cancer
  • Pregnant women
  • Men
  • Children

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03280836


Contacts
Layout table for location contacts
Contact: Kathleen M Sturgeon, PhD 717-531-0003 ext 284676 kms99@psu.edu
Contact: Kathryn H Schmitz, PhD 717-531-4387 kschmitz@phs.psu.edu

Locations
Layout table for location information
United States, Pennsylvania
Penn State Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Kathleen M Sturgeon, PhD    717-531-0003 ext 284676    kms99@psu.edu   
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Laney Smith    215-615-3245    Amanda.Smith4@uphs.upenn.edu   
Sponsors and Collaborators
Milton S. Hershey Medical Center
NRG Oncology
Investigators
Layout table for investigator information
Principal Investigator: Kathleen M Sturgeon, PhD Assistant Professor, Penn State
Layout table for additonal information
Responsible Party: Kathleen Sturgeon, Assistant Professor, Milton S. Hershey Medical Center
ClinicalTrials.gov Identifier: NCT03280836    
Other Study ID Numbers: 5517
First Posted: September 13, 2017    Key Record Dates
Last Update Posted: December 9, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases